Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Anti-Human P2X7 Monoclonal Antibody (Clone L4) Can Mediate Complement-Dependent Cytotoxicity of Human Leukocytes.
Eur J Immunol
January 2025
Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, Australia.
P2X7 is an extracellular adenosine 5'-triphosphate (ATP)-gated cation channel that plays various roles in inflammation and immunity. P2X7 is present on peripheral blood monocytes, dendritic cells (DCs), and innate and adaptive lymphocytes. The anti-human P2X7 monoclonal antibody (mAb; clone L4), used for immunolabelling P2X7 or blocking P2X7 activity, is a murine IgG2 antibody, but its ability to mediate complement-dependent cytotoxicity (CDC) is unknown.
View Article and Find Full Text PDFIdentification of anti-c, E alloantibodies with autoantibodies mimicking anti-c, E alloantibodies.
Heliyon
January 2025
Department of Laboratory Medicine, Shaoxing Central Hospital, Shaoxing, 312030, China.
Objectives: Autoantibodies mimicking alloantibodies (referred to as mimicking antibodies) are a type of specific antibody that reacts with all red blood cells, but exhibits a stronger reaction with red blood cells expressing the target antigens. This study aimed to explore immunohematologic methods for identifying mimicking antibodies, autoantibodies and alloantibodies, and to formulate safe transfusion strategies based on the results.
Methods: ABO, Rh blood types and direct antiglobulin test were determined using the tube saline method.
Serologic diagnosis of Entamoeba histolytica infection based on the gradient-based digital immunoassay.
Anal Chim Acta
February 2025
Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, PR China; Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, 200032, PR China. Electronic address:
Background: Entamoeba histolytica is a parasite that could cause severe amebiasis, an extremely contagious parasitic disease with critical clinical symptoms. Timely diagnosis and treatment of E. histolytica are crucial for preventing complications and fatalities.
View Article and Find Full Text PDFA phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors.
J Transl Med
January 2025
Scientia Clinical Research and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Background: A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors in a global multi-center phase Ia dose escalation trial.
Methods: In this phase Ia trial, a modified 3 + 3 study design was adopted during dose escalation phase. Eligible patients were enrolled, and GQ1001 monotherapy was administered intravenously every 3 weeks.
The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.
Hum Vaccin Immunother
December 2025
Department of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.
Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!